GGrantIndex
Sort

64,565 grants matching drug discovery

The Role of B cells in the Origin and Progression of Multiple Sclerosis

$1,129,237
Stephen L Hauser · University Of California, San Francisco · R35 · FY2023 · NS

Targeted Discovery of Marine-derived Anticancer Leads

$1,128,979
Phil Crews · University Of California Santa Cruz · U19 · FY2006 · CA

Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa

$1,128,851
David Elihu Greenberg · Ut Southwestern Medical Center · R01 · FY2020 · AI

Small-molecule inhibitors of flavivirus entry

$1,128,723
Priscilla Li-Ning Yang · Harvard Medical School · U19 · FY2015 · AI

Solvation modeling for next-gen biomolecule simulations

$1,128,699
Kenneth A Dill · State University New York Stony Brook · RM1 · FY2021 · GM

CMG2 as a target for safe and effective treatment of endometriosis-associate pain

$1,128,672
Michael Sean Rogers · Boston Children'S Hospital · R01 · FY2025 · HD

Emory-GSK-NIMH Collaborative Mood Disorders Initiative

$1,128,476
Charles B Nemeroff · Emory University · U19 · FY2006 · MH

Technology to Unmask Accessible Tumor Vascular Targets

$1,128,364
Sidney Kimmel Cancer Center · R33 · FY2002 · CA

Center for Interventional Oncology

$1,128,299
Bradford J Wood · Division Of Basic Sciences - Nci · ZID · FY2016 · CA

Coordinating Center for the Drug Induced Liver Injury Network (DILIN)

$1,128,182
Huiman X Barnhart · Duke University · U24 · FY2019 · DK

Targeting Epigenetic Circuits in B-Cell Lymphomas

$1,128,045
Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R35 · FY2020 · CA

The PIP2-virus interface and PI 4-kinase: novel biology and validation targets

$1,127,800
Jeffrey S Glenn · Stanford University · R01 · FY2012 · AI

Macrophages in Cardiovascular Health

$1,127,798
Matthias Nahrendorf · Massachusetts General Hospital · R35 · FY2025 · HL

The MetaCyc and BioCyc Pathway/Genome Databases

$1,127,776
Peter D Karp · Sri International · R01 · FY2008 · GM

The MetaCyc and BioCyc Pathway/Genome Databases

$1,127,776
Peter D Karp · Sri International · R01 · FY2009 · GM

Biomarker Signatures of TB Infection in Young Children With and Without HIV

$1,127,706
Padmini Salgame · Rutgers Biomedical And Health Sciences · R01 · FY2023 · AI

DCTD Human Toxicology and Pharmacology

$1,127,454
David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2016 · CA

Cancer Risk in Human Populations

$1,126,839
Debra Silverman · Division Of Cancer Epidemiology And Genetics · ZIA · FY2022 · CA

Bloomington Drosophila Stock Center at Indiana University

$1,126,777
Kevin R Cook · Trustees Of Indiana University · P40 · FY2024 · OD

Epigenomics of T cells and innate immune cells in human asthma

$1,126,630
Anjana Rao · La Jolla Institute For Immunology · R01 · FY2011 · HL

Development of an iPSC-derived human hepatocyte platform for drug development.

$1,126,573
Brian Robert Wamhoff · Hemoshear Therapeutics, Llc · R44 · FY2015 · GM

Development of a DIVI platform for issue resolution in pre-clinical drug development.

$1,126,395
Brian Robert Wamhoff · Hemoshear Therapeutics, Llc · R44 · FY2015 · GM

CONTROLLED RELEASE POLYMERS FOR BRAIN TUMORS (U19 CA 528

$1,125,634
Johns Hopkins University · U19 · FY2001 · CA

Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa

$1,125,531
David Elihu Greenberg · Ut Southwestern Medical Center · R01 · FY2023 · AI

A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTION

$1,125,092
Steven Carl George · University Of California At Davis · UH3 · FY2019 · HL